Patient-centered communication and shared decision making to reduce HbA1c levels of patients with poorly controlled type 2 diabetes mellitus - results of the cluster-randomized controlled DEBATE trial

Table 3 Changes of medication from baseline to 12 and 24 months follow-up among groups, between group differences, and interaction between group and time

		Intervention group							Control group						Between group differences
		Change from baseline							Change from baseline						Intervention group - Control group
Outcome variables	N	Mean	SD	Adjusted Mean	95% CI		p Value	N	Mean	SD	Adjusted Mean	95% CI		p Value	Adjusted Mean	95% CI		p Value
Sum of all diabetes medication
Baseline	435	1.98	0.8					398	2.02	0.8
12 months follow up	378	2.09	0.9	0.05	−0.03	0.12	0.2170	342	2.11	0.9	0.09	0.01	0.17	0.0274	−0.04	−0.14	0.06	0.4316
24 months follow up	339	2.14	0.9	0.14	0.06	0.22	0.0006	305	2.25	0.9	0.18	0.10	0.27	<.0001	−0.04	−0.14	0.06	0.4316
Insulin
Baseline	435	0.97	0.9					398	0.97	0.9
12 months follow up	378	1.08	0.9	0.09	0.03	0.15	0.0021	342	1.13	0.8	0.14	0.08	0.20	<.0001	−0.05	−0.12	0.03	0.2293
24 months follow up	339	1.17	0.9	0.20	0.14	0.26	<.0001	305	1.22	0.9	0.25	0.18	0.31	<.0001	−0.05	−0.12	0.03	0.2293
Sulfonylurea
Baseline	435	0.19	0.4					398	0.21	0.4
12 months follow up	378	0.20	0.4	−0.00	−0.04	0.03	0.8920	342	0.17	0.4	−0.02	−0.05	0.01	0.2591	0.02	−0.03	0.06	0.4506
24 months follow up	339	0.16	0.4	−0.04	− 0.08	−0.01	0.0195	305	0.15	0.4	−0.06	−0.10	− 0.02	0.0014	0.02	−0.03	0.06	0.4506
Other diabetes medication
Baseline	435	0.01	0.1					398	0.01	0.1
12 months follow up	378	0.02	0.1	0.01	−0.01	0.03	0.4477	342	0.03	0.2	0.01	−0.01	0.03	0.1829	−0.01	−0.03	0.02	0.6704
24 months follow up	339	0.05	0.2	0.04	0.02	0.07	0.0003	305	0.07	0.2	0.05	0.03	0.07	<.0001	−0.01	−0.03	0.02	0.6704

ISSN: 2731-4553